{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:59:00Z","timestamp":1793177940774,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jbspin.2012.09.009","type":"journal-article","created":{"date-parts":[[2012,11,27]],"date-time":"2012-11-27T00:06:45Z","timestamp":1353974805000},"page":"291-294","source":"Crossref","is-referenced-by-count":37,"title":["ACTH as first line treatment for acute gout in 181\u00a0hospitalized patients"],"prefix":"10.1016","volume":"80","author":[{"given":"Dimitrios","family":"Daoussis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Antonopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Yiannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Andonopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2012.09.009_bib0005","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0010","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3810\/pgm.2011.11.2511","article-title":"2011 recommendations for the diagnosis and management of gout and hyperuricemia","volume":"123","author":"Hamburger","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2011.12.006","article-title":"GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n=1003)","author":"Liote","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0002-9343(50)90004-0","article-title":"Effects of adrenocorticotropic hormone (ACTH) in gout","volume":"9","author":"Gutman","year":"1950","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.1780310618","article-title":"Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout","volume":"31","author":"Axelrod","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0045","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis","volume":"21","author":"Siegel","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0050","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.10526","article-title":"Activation of melanocortin type\u00a03 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis","volume":"46","author":"Getting","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/bmj.38975.390370.7C","article-title":"How to measure renal function in clinical practice","volume":"333","author":"Traynor","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0065","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.amjmed.2011.02.025","article-title":"Harmful effects of NSAIDs among patients with hypertension and coronary artery disease","volume":"124","author":"Bavry","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0070","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/CIRCULATIONAHA.110.004671","article-title":"Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study","volume":"123","author":"Schjerning Olsen","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0075","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0080","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/15563650.2011.589844","article-title":"Unrecognized fatalities related to colchicine in hospitalized patients","volume":"49","author":"Mullins","year":"2011","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0085","first-page":"696","article-title":"ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems","volume":"21","author":"Ritter","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.06.022","article-title":"Targeting melanocortin receptors as potential novel therapeutics","volume":"111","author":"Getting","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0100","first-page":"1064","article-title":"Arthritic diseases: melanocortin type 3 receptor agonists as potential therapeutics","volume":"2","author":"Getting","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1189\/jlb.69.1.98","article-title":"Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties","volume":"69","author":"Getting","year":"2001","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0110","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1096\/fj.06-6339com","article-title":"Melanocortin 3 receptors control crystal-induced inflammation","volume":"20","author":"Getting","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0115","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.4049\/jimmunol.162.12.7446","article-title":"POMC gene-derived peptides activate melanocortin type\u00a03 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation","volume":"162","author":"Getting","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0120","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2012.09.009_bib0125","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1200214X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X1200214X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T04:39:17Z","timestamp":1687840757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X1200214X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1297319X1200214X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2012.09.009","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}